Peptonic Medical (publ) (‘Peptonic’ or ‘Company’) today announced the results of a customer survey that was performed during spring/early summer this year among VagiVital users. It shows great user satisfaction and effective symptom relief. Of the nearly one hundred respondents, that had used VagiVital for one month or longer, 83 per cent reported symptom relief.
– We are of course very pleased with this outcome, which confirms the results of past customer surveys and clinical studies. That is, VagiVital provides strong symptom relief to those women suffering from vaginal atrophy and dryness, says Dr Johan Inborr, CEO of Peptonic Medical.
Among the respondents, approximately 1/3 said that they use VagiVital every second day, and approximately 1/3 every third day after the initial 30-day daily treatment period. Among those respondents that had previously used a competitor’s product, 89 per cent said that they would ‘most likely’ recommend VagiVital to a friend.
All answers have been treated anonymously and in strict confidence.
For more information, please contact;
Johan Inborr, CEO
Mobile: +46 708 853 893
This information is information that Peptonic Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 27th August, 2020.
VagiVital® is a patent pending hormone free self-care product for the treatment of vaginal atrophy and vaginal dryness. The product has been tested in randomised clinical studies (vaginal atrophy) with very positive results both for objective (vaginal pH and proportion of superficial cells in the vaginal mucosa) and subjective (most bothersome symptoms, such as vaginal dryness, vaginal irritation/itching, dyspareunia and dysuria) parameters. The magnitude of symptom relief is on par with that demonstrated with e.g. prescription estrogen based products on the market today. It was very well tolerated and caused no serious adverse effects.
VagiVital® was launched in Sweden as a non-prescription self-care product in July 2018 (see www.vagivital.com).
About Peptonic Medical
Peptonic Medical is an innovative Swedish medical development company. Its vision is to offer safe and effective treatments and relief for women specific diseases and medical conditions.
VagiVital® is a registered trademark of Peptonic Medical. The product is hormone free and is being commercialised for the non-prescription use for the treatment of vaginal atrophy (VA) and vaginal dryness. The pipeline of Peptonic Medical also includes Vagitocin®, which is an oxytocin-based vaginal gel for the treatment of VA. This product candidate is in clinical development phase 2. The development of Vagitocin® is on hold pending additional data on i.a. the mechanism of action.
Since July 2014, the Peptonic Medical share has been traded on the Spotlight Stock Exchange (www.spotlightstockmarket.se, ticker: PMED) in Stockholm, Sweden.
For more information: www.peptonicmedical.com